On the public citation graph

Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis

0 signed · 73 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2018.0049openalex-snapshot
Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR -Mutant Advanced Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1002/14651858.cd010383.pub2openalex-snapshot
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
inferredcites →https://doi.org/10.1002/ijc.23886openalex-snapshot
Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients
inferredcites →https://doi.org/10.1002/ijc.30806openalex-snapshot
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial
inferredcites →https://doi.org/10.1002/sim.1875openalex-snapshot
Combination of direct and indirect evidence in mixed treatment comparisons
inferredcites →https://doi.org/10.1007/s00262-006-0225-8openalex-snapshot
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
inferredcites →https://doi.org/10.1007/s11523-020-00708-yopenalex-snapshot
Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study
inferredcites →https://doi.org/10.1016/j.annonc.2020.08.2283openalex-snapshot
LBA50 ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
inferredcites →https://doi.org/10.1016/j.canlet.2008.02.064openalex-snapshot
Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals
inferredcites →https://doi.org/10.1016/j.jclinepi.2010.03.016openalex-snapshot
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
inferredcites →https://doi.org/10.1016/j.jcms.2010.11.001openalex-snapshot
Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias
inferredcites →https://doi.org/10.1016/j.jtho.2016.03.006openalex-snapshot
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation
inferredcites →https://doi.org/10.1016/j.jtho.2016.09.001openalex-snapshot
EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors
inferredcites →https://doi.org/10.1016/j.jtho.2018.09.004openalex-snapshot
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
inferredcites →https://doi.org/10.1016/j.jtho.2019.09.008openalex-snapshot
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
inferredcites →https://doi.org/10.1016/j.jval.2011.04.002openalex-snapshot
Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
inferredcites →https://doi.org/10.1016/j.lungcan.2013.01.018openalex-snapshot
Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
inferredcites →https://doi.org/10.1016/j.semcancer.2019.09.015openalex-snapshot
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
inferredcites →https://doi.org/10.1016/s1470-2045(09)70364-xopenalex-snapshot
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(11)70184-xopenalex-snapshot
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
inferredcites →https://doi.org/10.1016/s1470-2045(11)70393-xopenalex-snapshot
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(13)70604-1openalex-snapshot
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(14)70381-xopenalex-snapshot
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
inferredcites →https://doi.org/10.1016/s1470-2045(14)71173-8openalex-snapshot
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
inferredcites →https://doi.org/10.1016/s1470-2045(16)30033-xopenalex-snapshot
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30608-3openalex-snapshot
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(19)30035-xopenalex-snapshot
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(19)30634-5openalex-snapshot
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1038/ng.3990openalex-snapshot
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
inferredcites →https://doi.org/10.1038/nrc2088openalex-snapshot
Epidermal growth factor receptor mutations in lung cancer
inferredcites →https://doi.org/10.1056/nejmoa1713137openalex-snapshot
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1913662openalex-snapshot
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
inferredcites →https://doi.org/10.1080/10618600.1998.10474787openalex-snapshot
General Methods for Monitoring Convergence of Iterative Simulations
inferredcites →https://doi.org/10.1093/annonc/mdv270openalex-snapshot
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
inferredcites →https://doi.org/10.1093/annonc/mdv276openalex-snapshot
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
inferredcites →https://doi.org/10.1093/annonc/mdw611openalex-snapshot
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
inferredcites →https://doi.org/10.1093/annonc/mdx359openalex-snapshot
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
inferredcites →https://doi.org/10.1093/annonc/mdz260.002openalex-snapshot
CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
inferredcites →https://doi.org/10.1093/annonc/mdz399openalex-snapshot
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
inferredcites →https://doi.org/10.1097/jto.0b013e318227e8c6openalex-snapshot
Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations
inferredcites →https://doi.org/10.1097/jto.0b013e3182762bfbopenalex-snapshot
Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed
inferredcites →https://doi.org/10.1126/scitranslmed.3002003openalex-snapshot
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
inferredcites →https://doi.org/10.1136/bmj.327.7414.557openalex-snapshot
Measuring inconsistency in meta-analyses
inferredcites →https://doi.org/10.1136/bmj.l5460openalex-snapshot
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
inferredcites →https://doi.org/10.1158/0008-5472.can-05-0641openalex-snapshot
Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein
inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-1846openalex-snapshot
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
inferredcites →https://doi.org/10.1158/1078-0432.ccr-06-0462openalex-snapshot
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-2246openalex-snapshot
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
inferredcites →https://doi.org/10.1172/jci43656openalex-snapshot
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
inferredcites →https://doi.org/10.1186/s12943-018-0777-1openalex-snapshot
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
inferredcites →https://doi.org/10.1200/jco.19.01154openalex-snapshot
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer
inferredcites →https://doi.org/10.1200/jco.19.01488openalex-snapshot
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
inferredcites →https://doi.org/10.1200/jco.2012.44.2806openalex-snapshot
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
inferredcites →https://doi.org/10.1200/jco.2014.58.1736openalex-snapshot
Impact of Specific Epidermal Growth Factor Receptor ( EGFR ) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR -Mutant Lung Cancer: A Meta-Analysis
inferredcites →https://doi.org/10.1200/jco.2016.66.9218openalex-snapshot
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.9007openalex-snapshot
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.
inferredcites →https://doi.org/10.1200/jco.2018.78.7994openalex-snapshot
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.9506openalex-snapshot
NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
inferredcites →https://doi.org/10.1371/journal.pone.0076654openalex-snapshot
Graphical Tools for Network Meta-Analysis in STATA
inferredcites →https://doi.org/10.2217/lmt-2020-0011openalex-snapshot
Efficacy and Safety of Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation: a Network Meta-Analysis
inferredcites →https://doi.org/10.3322/caac.21262openalex-snapshot
Global cancer statistics, 2012

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4672163openalex-extracted
Successful Therapy of A Critically Ill Nsclc Patient With Uncommon Mutations in Egfr G719x and S768i Genes Using Furmonertinib: A Case Report
inferred← citeshttps://doi.org/10.1002/jbt.70427openalex-snapshot
Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities
inferred← citeshttps://doi.org/10.1007/s11523-022-00868-zopenalex-snapshot
Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2022.103760openalex-snapshot
Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ctrv.2023.102561openalex-snapshot
Proteolysis targeting chimeras in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e27106openalex-snapshot
Successful therapy of a critically ill non-small cell lung cancer patient with compound mutations in EGFR G719X and S768I genes using furmonertinib: A case report
inferred← citeshttps://doi.org/10.1177/1721727x221145447openalex-snapshot
Observation on the clinical efficacy and side effects of EGFR-TKI ± chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma
inferred← citeshttps://doi.org/10.1186/s12885-022-09592-3openalex-snapshot
Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis
inferred← citeshttps://doi.org/10.1186/s12890-024-03292-3openalex-snapshot
Successful rapid improvement of acute respiratory distress syndrome induced by EGFR-mutated non-small cell lung cancer with almonertinib: a case report
inferred← citeshttps://doi.org/10.3390/cancers14194894openalex-snapshot
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.27124177openalex-snapshot
Additional file 1 of Successful rapid improvement of acute respiratory distress syndrome induced by EGFR-mutated non-small cell lung cancer with almonertinib: a case report
inferred← citeshttps://doi.org/10.6084/m9.figshare.27124180openalex-snapshot
Additional file 2 of Successful rapid improvement of acute respiratory distress syndrome induced by EGFR-mutated non-small cell lung cancer with almonertinib: a case report
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.